Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment

Shruti Rao, Robert A. Beckman, Shahla Riazi, Cinthya S. Yabar, Simina M. Boca, John L. Marshall, Michael J. Pishvaian, Jonathan R. Brody, Subha Madhavan

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic context of chemopredictive biomarkers. We extensively surveyed public literature to systematically review the predictive effect of 7 biomarkers claimed to predict response to various chemotherapy drugs: ERCC1-platinums, RRM1-gemcitabine, TYMS-5-fluorouracil/Capecitabine, TUBB3- taxanes, MGMT-temozolomide, TOP1-irinotecan/topotecan, and TOP2A-anthracyclines. We focused on studies that investigated changes in gene or protein expression as predictors of drug sensitivity or resistance. We considered an evidence framework that ranked studies from high level I evidence for randomized controlled trials to low level IV evidence for pre-clinical studies and patient case studies. We found that further in-depth analysis will be required to explore methodological issues, inconsistencies between studies, and tumor specific effects present even within high evidence level studies. Some of these nuances will lend themselves to automation, others will require manual curation. However, the comprehensive cataloging and analysis of dispersed public data utilizing an evidence framework provides a high level perspective on clinical actionability of these protein biomarkers. This framework and perspective will ultimately facilitate clinical trial design as well as therapeutic decision-making for individual patients.

Original languageEnglish (US)
Pages (from-to)37923-37934
Number of pages12
Issue number23
StatePublished - 2017
Externally publishedYes


  • Biocuration
  • Clinical utility
  • Evidence framework
  • Precision medicine
  • Predictive biomarkers

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment'. Together they form a unique fingerprint.

Cite this